Thylacine Biotherapeutics
Miami Beach, US · Founded 2021 · Delaware corporation
Founders & leadership
RG
Robert GraifmanNamed on SEC filing
DG
Daniel GraifmanNamed on SEC filing
AF
Andrew FradkinNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$476K disclosed across 1 round · 2023
▶$476KraisedJan 2023 · 13 investors · BiotechnologyRule 506(b)
▶$476KraisedJan 2023 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert GraifmanDirector
- Daniel GraifmanExecutive Officer, Director
- Andrew FradkinDirector
- Offering amount
- $1M
- Amount sold
- $476K
- Minimum investment
- $5K
- Sales commissions
- $70K
- Proceeds to insiders
- $100K
- Placement agents
- Walter Greenblatt & Assoc
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Thylacine Biotherapeutics raised?
- Thylacine Biotherapeutics has disclosed $476K raised across 1 round.
- Where is Thylacine Biotherapeutics headquartered?
- Thylacine Biotherapeutics is headquartered in Miami Beach, US.